RAD52

Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Wednesday, November 23, 2022
RAD52, Histology, Therapy, Genetics, Patient, Online shopping, Pharmaceutical industry

A copy of the presentation materials can be accessed by visiting the " Resources section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.

Key Points: 
  • A copy of the presentation materials can be accessed by visiting the " Resources section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.
  • Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit.
  • This approach includes using a tumor-agnostic strategy to select patients based on their tumors underlying genetics rather than histology.
  • In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Rain Therapeutics to Participate in Piper Sandler’s 34th Annual Healthcare Conference

Retrieved on: 
Friday, November 18, 2022
Therapy, RAD52, Histology, Genetics, Patient, RAIN, Conference, Pharmaceutical industry

NEWARK, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will be participating in Piper Sandlers 34th Annual Healthcare Conference, being held November 29 December 1, 2022, in New York.

Key Points: 
  • NEWARK, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will be participating in Piper Sandlers 34th Annual Healthcare Conference, being held November 29 December 1, 2022, in New York.
  • Avanish Vellanki, chief executive officer of Rain, will be participating in a fireside chat on Thursday, December 1 at 1:30 p.m.
  • Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit.
  • In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting

Retrieved on: 
Thursday, November 17, 2022
RAD52, Histology, Therapy, Memorial Sloan Kettering Cancer Center, Genetics, Patient, Associate, Pharmaceutical industry

Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit.

Key Points: 
  • Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit.
  • This approach includes using a tumor-agnostic strategy to select patients based on their tumors underlying genetics rather than histology.
  • Rains lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53.
  • In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Rain Therapeutics to Participate in H.C. Wainwright’s 3rd Annual Precision Oncology Virtual Conference

Retrieved on: 
Monday, November 14, 2022
Therapy, RAIN, Histology, RAD52, Conference, Genetics, Patient, Pharmaceutical industry

NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain) a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in H.C. Wainwrights 3rd Annual Precision Oncology Conference on November 14, 2022.

Key Points: 
  • NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain) a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in H.C. Wainwrights 3rd Annual Precision Oncology Conference on November 14, 2022.
  • Company management will participate in one-on-one investor meetings, and Avanish Vellanki, CEO, will be participating in a fireside chat on Monday, November 14 at 1:00 PM ET.
  • Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit.
  • In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Rain Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Private Securities Litigation Reform Act, IO, PRS, Health, Investment, Doctor of Philosophy, U.S. Securities and Exchange Commission, Liposarcoma, Nasdaq, CDKN2A, Food, Webcast, Daiichi Sankyo, Research, RAD52, G&A, COVID-19, RECIST, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Genetics, R, Safety, International, LPS, Histology, RAIN, Coronavirus Scientific Advisory Board (Turkey), Clinical trial, Biotechnology, Patient, Corporation, Security (finance), Progression-free survival, Bachelor of Medicine, Bachelor of Surgery, MD, Biliary tract, FDA, MDM2, Pharmaceutical industry, Medical imaging, Management

We plan to initiate the MANTRA-4 trial next quarter and remain very excited about this second tumor agnostic basket strategy.

Key Points: 
  • We plan to initiate the MANTRA-4 trial next quarter and remain very excited about this second tumor agnostic basket strategy.
  • As of September 30, 2022, Rain had $90.7 million in cash, cash equivalents and short-term investments as compared to $140.2 million at December 31, 2021.
  • As of September 30, 2022, Rain had approximately 26.6 million shares of common stock outstanding.
  • The management of Rain Therapeutics will host a conference call and webcast for the investment community today, November 10, 2022 at 2:00 pm PT (5:00 pm ET).

Rain Therapeutics Announces $50 Million Registered Offering of Common Stock

Retrieved on: 
Friday, November 4, 2022
Janus, Park, Private Securities Litigation Reform Act, Prospectus, Telephone, Therapy, LLC, Histology, SEC filing, Sale, Attention, GLOBE, Madison Avenue, Floor, Guggenheim Partners, Genetics, RAD52, Nasdaq, U.S. Securities and Exchange Commission, Suite, Form, Tertiary Institutions Service Centre, Security (finance), RAIN, SEC, S-3, Patient, Pharmaceutical industry

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting common stock.

Key Points: 
  • NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting common stock.
  • The shares of non-voting common stock are convertible into an equal number of shares of common stock, subject to beneficial ownership limitations.
  • The gross proceeds to Rain, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $50 million.
  • Rain has granted the underwriters a 30-day overallotment option to purchase up to 1,286,449 additional shares of common stock at the offering price, less underwriting discounts and commissions.

Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)

Retrieved on: 
Friday, November 4, 2022
Private Securities Litigation Reform Act, Progression-free survival, RECIST, Therapy, LPS, Oncogene, CN, Histology, Food, PRS, Corporation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, EGFR, FDA, Safety, KRAS, Neoplasm, CDKN2A, COVID-19, Genetics, RAD52, PIK3CA, MANTRA, Nasdaq, U.S. Securities and Exchange Commission, Clinical trial, Data, MDM2, Cancer, Health, Liposarcoma, Security (finance), RAIN, Bachelor of Medicine, Bachelor of Surgery, Patient, Biliary tract, Pharmaceutical industry, Medical imaging

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead clinical candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced preliminary data in the multicenter, single arm, open-label, Phase 2 basket trial evaluating milademetan, an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of MDM2-amplified advanced solid tumors.

Key Points: 
  • We are encouraged by the preliminary observations from the MANTRA-2 trial, said Avanish Vellanki, co-founder and chief executive officer of Rain.
  • In addition, anti-tumor activity was observed in patients with genetic co-alterations, and in tumors with MDM2 copy number above 8.
  • Hence, we plan to revise the protocol to include patients tested locally for MDM2 copy number of 8 and greater.
  • Rain has completed enrollment in a Phase 3 trial of milademetan (MANTRA) in patients with LPS, and is evaluating milademetan in a Phase 2 tumor-agnostic basket trial in certain solid tumors (MANTRA-2).

Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022

Retrieved on: 
Thursday, October 27, 2022
Nasdaq, Therapy, RAIN, Histology, Genetics, Webcast, GLOBE, RAD52, Conference, Patient, Pharmaceutical industry

NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022.

Key Points: 
  • NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022.
  • On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Companys business and financial results.
  • This approach includes using a tumor-agnostic strategy to select patients based on their tumors underlying genetics rather than histology.
  • In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium

Retrieved on: 
Wednesday, October 26, 2022
Histology, Mace Head Atmospheric Research Station, Genetics, RAD52, Therapy, Patient, Pharmaceutical industry

Vijaya G. Tirunagaru, Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics, Newark, CA

Key Points: 
  • Vijaya G. Tirunagaru, Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics, Newark, CA
    A copy of the presentation materials can be accessed by visiting the " Resources section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.
  • Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit.
  • This approach includes using a tumor-agnostic strategy to select patients based on their tumors underlying genetics rather than histology.
  • In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Rain Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference

Retrieved on: 
Wednesday, August 31, 2022
CEO, Four Seasons Hotels and Resorts, Genetics, Therapy, Nasdaq, Season, Histology, GLOBE, Citigroup, RAD52, Conference, RAIN, Patient, Pharmaceutical industry

NEWARK, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in Citis 17th Annual BioPharma Conference on September 7-8, 2022 taking place at the Four Seasons Hotel in Boston, MA.

Key Points: 
  • NEWARK, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in Citis 17th Annual BioPharma Conference on September 7-8, 2022 taking place at the Four Seasons Hotel in Boston, MA.
  • Company management will participate in one-on-one investor meetings, and Avanish Vellanki, CEO, will be participating in a company panel for targeted oncology on Thursday, September 8 at 2:40-3:25 PM ET.
  • Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit.
  • In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.